ArticlePhysics and imaging in radiation oncology2026
Dose comparison of proton beam therapy with and without a multileaf collimator in the treatment of multiple hepatocellular carcinoma.
Article in Physics and imaging in radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Proton beam therapy (PBT) offers dosimetric advantages over conventional photon-based radiation therapy in treating hepatocellular carcinoma (HCC) because it more effectively spares normal liver tissue. This study investigated the potential benefits of incorporating a multileaf collimator (MLC) into PBT to further reduce the radiation exposure of normal liver tissues. Materials and methods: We compared eighteen PBT treatment plans with and without MLC implementation, focusing on normal liver dose metrics. Two normal-tissue complication probability (NTCP) models were used to evaluate treatment-related liver side effects. Additionally, we examined the correlation between the characteristics of multiple treatment targets and the volume of liver sparing at low doses to determine the criteria for MLC application. Results: The V Conclusions: The integration of MLC into PBT planning effectively reduced low-dose spread and increased normal liver sparing, potentially lowering the risk of radiation-induced liver side effects. However, the associated increase in the maximum dose at shallow depths warrants careful consideration during plan optimization. The spatial relationship between multiple lesions may serve as a useful criterion for selecting MLC use in clinical settings involving multiple targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.